Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report

Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC w...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Po-Lan, Lin, Chien-Yu, Chen, Yi-Lin, Chen, Wan-Li, Lin, Chien-Chung, Su, Wu-Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474392/
https://www.ncbi.nlm.nih.gov/pubmed/34590045
http://dx.doi.org/10.1016/j.jtocrr.2021.100202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474392/
https://www.ncbi.nlm.nih.gov/pubmed/34590045
http://dx.doi.org/10.1016/j.jtocrr.2021.100202

Ejemplares similares